The ATS gratefully acknowledges the following members of our society who’ve donated their time to develop this pioneering event. If you’d like to be considered for the 2025 Advisory Board, please email your CV to dbell@thoracic.org
All advisors have met ATS requirements for disclosure of conflicts of interest and attested compliance with the ATS Professionalism and Ethical Conduct Policy.
Kimberly Armstrong
Kimberly Armstrong, Ph.D., MT (ASCP) is the Director of the Influenza and Emerging Infectious Diseases Division (IEIDD) at the Biomedical Advanced Research and Development Authority (BARDA) within the Administration for Strategic Preparedness and Response (ASPR) at the Department for Health and Human Services. IEIDD is focused on preparing for the next influenza pandemic by modernizing influenza vaccines, developing new therapeutics for the treatment of acute respiratory distress syndrome, protecting the most vulnerable populations with pre-exposure prophylaxis options, and managing the National Pre-pandemic Influenza Vaccine Stockpile. IEIDD’s response efforts are evident in the response to the COVID-19 pandemic where vaccines and therapeutics were developed, tested, and authorized in record time. In addition to influenza and COVID-19, the division has invested in vaccines to protect against Zika virus infection as well as enabling vaccine technologies to support delivery of vaccines without needles and syringes.
Prior to becoming the Division Director in 2023, Dr. Armstrong was the Chief of the Therapeutics Branch within IEIDD. Her work within the branch focused on testing antivirals for the treatment of hospitalized influenza infections and eventually pivoting the program for severe infections from antivirals to host-directed therapeutics. In addition, during the COVID-19 pandemic, Dr. Armstrong led the therapeutics team to achieve Emergency Use Authorizations for 10 therapeutics and procurement of millions of treatment courses of COVID-19 antivirals that have been distributed across the country.
Before joining BARDA in 2015 as a project officer, Dr. Armstrong managed a regulatory science research portfolio for the Office of Counterterrorism and Emerging Threats at the Food and Drug Administration (FDA). Dr. Armstrong joined the federal government as a Presidential Management Fellow at the Defense Threat Reduction Agency (DTRA). She received her Ph.D. from the Harvard Graduate School of Arts and Sciences in Biological Sciences in Public Health where her work focused on drug resistance in the human immunodeficiency virus (HIV). Dr. Armstrong received her certification as a medical technologist from the American Society for Clinical Pathology.
Todd Austin
Todd Austin has a career spanning 20 years and is a globally recognized clinical and medical device industry expert and leader with extensive experience in product development and marketing, strategic planning, business development, P&L responsibility, and clinical consulting. In recent years Mr. Austin has provided clinical, strategic, and tactical consulting services to senior management for several domestic and international healthcare companies.
Mr. Austin holds a Bachelor of Science degree from Mount Marty College and is a Registered Respiratory Therapist, Neonatal-Pediatric Specialist and Registered Pulmonary Function Technologist. Mr. Austin is member of the American Association of Respiratory Care, American Thoracic Society, European Respiratory Society, Canadian Society of Respiratory Therapists, The Association for Respiratory Technology & Physiology, and Thoracic Society of Australia and New Zealand.
Mr. Austin is currently Executive Vice President of Global Business Development for CAIRE, Inc. a Niterra Group Company. From 2014 to 2023 Mr. Austin served as a public and sponsored Chief Executive Officer for MGC Diagnostics, prior to that as Executive Vice President Global Marketing, Engineering, and Corporate Strategy from 2012 to 2014.
From 2006 to 2010 Mr. Austin was Director of Marketing for CareFusion (now Vyaire). Prior to CareFusion (now Vyaire) Mr. Austin served as Vice President – U.S. Sales and Marketing for ndd Medical Technologies, a Zurich, Switzerland-based company. Mr. Austin also served as Group Product Manager for Yorba Linda, California-based VIASYS Healthcare and Customer/Product Support and Applications Manager for SensorMedics Corporation.
Jamil Beg
Jamil is a life science investor and company builder focused on advancing breakthrough science into transformational medicines for patients. Jamil joined SV Health Investors in January 2024 and is a Partner based in Boston. He works with founders, entrepreneurs, operators, and co-investors to establish and build new biotech startups, as well as fund and grow established private biotech companies across any stage of investment.
Prior to joining SV, Jamil founded and operated several biotech startups as well as invested across therapeutic areas, stages of technology platforms/assets, and modalities. Over his career, Jamil has been involved in over twenty private financings, seven public offerings, and three M&A transactions. He has operated in six venture-backed startups and contributed to the advancement of multiple FDA approved products. Select investments and operating roles include Akouos (NASDAQ: AKUS, acquired by Eli Lilly), Aprea (NASDAQ: APRE), Kinaset Therapeutics (founding investor), Nido Biosciences (founder), RallyBio (NASDAQ: RLYB), Sage Therapeutics (NASDAQ: SAGE), and Transave Inhalation Therapeutics (merged with Insmed). Jamil brings a wealth of entrepreneurial and operational expertise from his time building companies like Sage Therapeutics and Nido Biosciences and founding several stealth biotech startups.
Jamil earned his B.S.E. in Bioengineering and Master of Biotechnology degrees from the University of Pennsylvania. He earned his M.B.A. in Healthcare Management and Entrepreneurial Management from The Wharton School of the University of Pennsylvania where he was a recipient of the Henry J. Kaiser Family Foundation Merit Award.
Alan Cohen, MD
Alan H. Cohen, MD is a board-certified Pediatric Pulmonologist, as well as a Lung Transplant and Cystic Fibrosis physician. He has worked at several highly regarded Pulmonary Centers of Excellence, including those at the University of Colorado/National Jewish, Washington University School of Medicine, Emory University, Johns Hopkins and Stanford University School of Medicine.
Alan currently serves as the Senior Vice President of Clinical Development and Therapeutic Area Head of Pulmonary Medicine at 4D Molecular Therapeutics. He is leading the gene therapy programs in CF and other cardiopulmonary disease targets including Fabry Disease.
In addition to his many years of clinical practice, biomedical and basic science research, and teaching, he has dedicated over 20+ years of his 30+ years professional career to drug discovery, in the Biotech & Pharma clinical/medical research space, at both small, entrepreneurial pre-IPO start-ups, as well as more well-established public companies worldwide.
His research and drug development career have included roles of increasing responsibility and leadership at companies such as: Metagenomi (SVP/CMO Clin Dev Gene Editing), Eidos/BridgeBio (VP), Bayer (GCL), Aridis Pharma (SVP), Therabron Therapeutics (SVP/CMO), Eddingpharm (CMO), Boehringer Ingelheim, InterMune (SVP - acquired by Roche / Genentech), MAP Pharma (VP - acquired by Allergan), Jazz Pharma (CMO/VP) & Medimmune (acquired Astra Zeneca).
Dr. Cohen has remained clinically active throughout his professional medical career, including direct patient care as well as teaching medical students, residents and fellows, most recently serving as adjunct clinical and teaching faculty at Stanford University School of Medicine – in the Dept. of Pediatric Pulmonology.
Courtney Crim, MD, ATSF
Courtney Crim, MD currently is Clinical Associate Professor of Medicine in the Division of Pulmonary and Critical Care Medicine at the University of North Carolina in Chapel Hill. He also serves on the Drug/Device Discovery and Development Committee and assumed the role of Chair in 2021. Formerly, he was Group Director in Clinical Development in Respiratory Clinical Sciences at GlaxoSmithKline. He had approximately 22 years of experience designing Phase II-IV clinical trials that encompassed developing new medical entities. Prior, he was a member of the US FDA Pulmonary and Allergy Drug Advisory Committee, and has also presented submissions for drug approval at US, European and other country regulatory agencies.
Dr. Crim holds a Doctorate in Medicine from the University of Michigan Medical School. He completed post-graduate training in Internal Medicine at Baylor College of Medicine in Houston and Henry Ford Hospital in Detroit, with sub-specialty training in Pulmonary & Critical Care Medicine at the University of Michigan. He is certified by the American Board of Internal Medicine (ABIM) in Internal Medicine, Pulmonary Diseases and Critical Care Medicine. He has presented at national and international meetings on respiratory disorders, such as pneumonia, asthma and COPD. Dr. Crim has written several book chapters and authored or co-authored over 100 manuscripts that are published in per-reviewed medical journals. He has also served as a reviewer for the journals Chest, the European Respiratory Journal and the American Journal of Respiratory and Critical Care Medicine.
Aryeh Fischer, MD
Dr. Fischer transitioned from an academic medicine in August 2019 to pursue drug development in lung fibrosis at BMS. Prior to joining industry, he served as Associate Professor of Medicine, Division of Rheumatology and Division of Pulmonary Sciences and Critical Care Medicine at the University of Colorado where he was Director of the Autoimmune and Fibrotic Lung Disease Treatment Program.
His clinical and research interests have primarily been within the arena of autoimmune forms of interstitial lung disease (ILD). Through my research he has demonstrated the importance of precise phenotyping of autoimmune forms of ILD, led the ATS/ERS Task Force that developed the concept/classification of interstitial pneumonia with autoimmune features (IPAF) and have been a steering committee member, clinical researcher and principal investigator on numerous studies and clinical trials involved in identifying new therapies for management of ILD.
Dr. Fischer has authored > 100 peer-reviewed articles and numerous book chapters – the vast majority of which regarding the topic of autoimmune and fibrotic ILD. I have been honored with opportunities to lecture extensively and globally in this arena. I have been fortunate to help demonstrate the importance of interdisciplinary engagement in the clinical care and research of ILD, and in particular for bridging gaps between immunology, rheumatology and pulmonary in this arena.
Joel Moss, MD, PhD, ATSF
Joel Moss, MD, PhD is Deputy Chief of the Pulmonary Branch, NHLBI, NIH and Head of the Laboratory of Translational Research. He graduated Brandeis University, summa cum laude, and received M.D.- Ph.D. degrees from NYU School of Medicine. Internship and residency (medicine; Johns Hopkins) were followed by a pulmonary fellowship (NHLBI). He is a member of Phi Beta Kappa and Alpha Omega Alpha. He has co-authored over 750 scientific papers, co-edited several books, and is a co-inventor of biotechnology patents. A past member of the NHLBI Institutional Review Board and its Chair from 1995-2006, he co-authored texts on ethical considerations in clinical research. Dr. Moss has received multiple awards, including the NIH Director’s Award, LAM Foundation Awards, and the NYU Alumni Achievement Award in Basic Science. He is an honorary member of the Peruvian Thoracic Society and received the Chiba (Japan) Medical Society Award. A member of American Society for Clinical Investigation for which he was a Councilor and Vice-President, he was elected to the Association of American Physicians and Johns Hopkins University Society of Scholars. He is a Fellow of the ACCP and ATS and currently an Editor of AJRCMB and CHEST. His research program focuses on Lymphangioleiomyomatosis and other cystic lung diseases, with emphasis on mechanisms of lung destruction and the use of imaging to visualize injury. His other research interest is in ADP-ribosylation, a reversible modification of proteins and other acceptors, and a reaction used by bacterial toxins and mammalian cells to modulate critical biological processes.
Ahmed Mousa, JD, MS
Ahmed Mousa is the Chief Executive Officer of Vicore Pharma with an extensive background in business and corporate development, portfolio strategy, and entrepreneurial experience in the life sciences industry. Prior to joining Vicore, Ahmed was the Chief Business Officer & General Counsel of Pieris Pharmaceuticals where he played a key role in development of the company’s pipeline and execution of strategic collaborations with a range of pharmaceutical companies. Ahmed previously was an attorney representing life sciences companies in a range of matters at Covington & Burling and Kirkland & Ellis. Ahmed received undergraduate degrees in molecular biology and government from Cornell University, a master’s degree in biotechnology from Johns Hopkins University, and a law degree from Georgetown with honors.
Charles Powell, MD, MBA
Charles A Powell, MD, MBA, is Professor of Medicine and System Division Chief for Pulmonary, Critical Care, and Sleep Medicine at the Icahn School of Medicine at Mount Sinai. The Division is ranked #8 Globally and #1 in New York for Pulmonary Specialties by Newsweek.
Dr. Powell earned his bachelor’s degree in economics from the University of Pennsylvania before completing his medical degree at the University of Chicago. He trained in Internal Medicine at Columbia University and in Pulmonary and Critical Care Medicine at Boston University. He also holds an MBA from Yale University.
Dr. Powell is CEO of the Mount Sinai Respiratory Institute LLC, which brings together leading expertise in diagnosing and treating all forms of respiratory illness and lung disease, including asthma, lung cancer, chronic obstructive pulmonary disease, interstitial lung disease, and bronchiectasis.
Dr. Powell’s primary Pulmonary Disease focus is on the research and treatment of lung nodules and cancer. Dr. Powell is funded by the National Institutes of Health (NIH), has published over 150 articles, and directs an NIH-funded translational sciences laboratory that examines the genomics of lung cancer. Dr. Powell’s particular area of interest is on deconvoluting the biology and genomics of early stage lung adenocarcinoma, for which recent advances have modified the diagnosis and approach to these tumors. He is an international expert in the diagnosis and management of drug induced lung injury in patients treated with advanced cancer medications such as antibody drug conjugates and immunotherapy. He also directs research programs focused on applications of machine learning and artificial intelligence to advance the diagnosis and treatment of respiratory diseases.
Dr. Powell’s international reputation in the field is demonstrated by his election as President of the Fleischner Society and by his leadership roles in the International Society of Respiratory Disease. He is chair of the International Multidisciplinary Adjudication Committee to evaluate interstitial lung disease adverse events in cancer clinical trials of antibody-drug conjugates.
Rachel Rath, MPH, MBA
Rachel is the Director of the BARDA Alliance for Johnson & Johnson Innovation, based at Johnson & Johnson Innovation – JLABS (JLABS) in Washington, DC. As BARDA Alliance Director, she is responsible for managing BLUE KNIGHT™, a joint initiative between JLABS and the Biomedical Advanced Research and Development Authority (BARDA), which aims to stimulate the innovation and incubation of science and technologies. Rachel leads the strategic direction, alliance management, and oversight of all operational activities related to the collaboration with BARDA, including managing the sourcing and selection of high potential companies for JLABS locations and developing global programming.
Before joining JLABS, Rachel was the Chief of Staff for the National Evaluation System for health Technology Coordinating Center (NESTcc)—an initiative of the Medical Device Innovation Consortium (MDIC)—that was established with funding from the U.S. Food and Drug Administration (FDA) and was recognized in September 2019 as one of the first collaborative communities with participation by the FDA. Prior to joining NESTcc, Rachel worked at PCORI, helping to launch the Patient-Centered Clinical Research Network (PCORnet), a national effort to engage patients and leverage electronic health data to improve the speed and efficiency of clinical research in the United States.
Rachel received her MBA from Georgetown University and MPH in global health policy from The George Washington University.
Joe Reif, MBA
Joe currently serves as the Vice President, Business & Clinical Development at VIDA Diagnostics. He has spent his entire career in Healthcare, primarily in the pharmaceutical sector where he has led commercial sales teams responsible for new product launches across a variety of therapeutic areas. In addition, Joe has worked in clinical trials as a Senior Administrator at Rush University Medical Center in Chicago. He received his B.S. from St. John’s University, MN and an MBA from the University of Notre Dame, IN.
Colin Reisner, MD, ATSF
Dr. Colin Reisner is CEO and co-founder of DevPro Biopharma, a clinical research and development accelerator focused on accelerating Respiratory and Immunology programs. Prior to DevPro, he was the Senior Vice President and Head of Late Stage Respiratory, Inflammation & Autoimmunity, R&D, AstraZeneca. He is an innovative leader with more than 25 years of international experience at top-tier companies, having previously worked at Boehringer Ingelheim, GSK, and Novartis. Colin has extensive experience in large and small companies, formerly both CMO and CEO of Pearl Therapeutics.
As CEO of DevPro, he is responsible for the strategic design of clinical programs for clients at different stages of development, from First in Human to large registration programs.
Colin's passion for improving patients' lives fuels his active involvement in developing inhaled, oral, and biologics products from concept through Global approval. He is a well-respected thought leader, often presenting at international congresses and publishing extensively in high-quality journals, including NEJM, JAMA, Lancet, AJRCCM, and CHEST.
Colin attended medical school at the University of Witwatersrand, Johannesburg, South Africa. He received specialist training in internal medicine at a Yale-affiliated program, followed by sub-specialty training in Allergy-Immunology at National Jewish, Denver, CO. He previously held adjunct faculty positions at Yale and Duke University. A Diplomate of the American Board of Allergy and Immunology, Fellow of the American College of Chest Physicians, American Academy of Allergy, Asthma & Immunology, and the American Thoracic Society.
Theodore Reiss, MD, MBE, ATSF
Dr. Ted Reiss, now a retired pharma development consultant, was most recently Executive Vice President and CMO at Repertoire Immune Medicines. Previous positions included Venture Partner, Novo Ventures, Head, Global Clinical Research and Development, I&I at Celgene, Global Clinical Development Head, Primary Care at Novartis, Research Professor of Medicine at Vanderbilt University, as well as Global Head, Integrated Drug Development at Covance, focusing on developing an integrated translational research program.
Dr. Reiss also spent 18 years at Merck Research Laboratories where he was Vice President of Clinical Sciences. Notably, he guided the development of montelukast from first in man through its life cycle, and had leadership roles in the development of alendronate, and aprepitant. Ted also played a key role in various company-wide process optimization efforts including the effort to optimize site allocation, selection, and patient recruitment, and the Development Portfolio Management and Outsourcing Model.
Ted served on the FDA Pulmonary Advisory Committee. He presently serves as a member the Commissioner’s FDA Science Board. He is a past Chair of the American Thoracic Society (ATS) Drug, Device, Discovery, and Development Committee, served on the Board of Directors of the ATS, was chair of the Funds for the Future Committee, was a keynote speaker at the 2018 ATS International Conference, and is serving again on the Ethics and Conflict of Interest Committee. Ted has been a lecturer in the Master in Translational Research program at the University of Pennsylvania and at Vanderbilt. He presently serves as a member of the Advisory Board at Koneksa Health is a Board Advisor for Aerami Therapeutics.
In addition to publishing over 100 peer-reviewed papers, Dr. Reiss was a recipient of the Merck Directors’ Award, the company’s highest honor for his scientific achievements. He is a fellow of the American Thoracic Society and recently received from the ATS the Presidential Accomplishment Award and the Distinguished Career Award.
Ted received his undergraduate degree in molecular biology and US history from the University of Pennsylvania, an M.D. from Vanderbilt University, and a Masters in Bioethics from the University of Pennsylvania School of Medicine. Ted completed his internal medicine training at the Presbyterian Hospital of Columbia University. He performed clinical respiratory and critical care as well as research training in airway pharmacology and immunology at the Cardiovascular Research Institute, the University of California, San Francisco.
Albert Rizzo, MD
Dr. Albert A. Rizzo is the Chief Medical Officer for the American Lung Association and practices pulmonary/sleep medicine at Christiana Care in Newark, Delaware. He is board-certified in internal medicine, pulmonary, critical care and sleep medicine and is a Clinical Assistant Professor of Medicine at the Sidney Kimmel Medical College at Thomas Jefferson University in Philadelphia where he obtained his medical degree (1978) and completed his residency in Internal Medicine (1978-1981) He received his specialty training at Georgetown University Hospital in Wash DC. (1981-1983) He is a member of the American Thoracic Society, a Fellow of the American College of Chest Physicians and the American College of Physicians and the American Association of Sleep Medicine and a Diplomat of the American Board of Sleep Medicine.
His out-patient practice of over 39 years covers general pulmonary and sleep medicine disorders and includes a strong interest in asthma, COPD, pulmonary fibrosis, pulmonary rehabilitation, lung cancer and obstructive sleep apnea. Since the impact of COVID, he has transitioned to a totally virtual practice in the ChristianaCare Center for Virtual Health as the pulmonary specialist.
He has held administrative duties at Christiana Care Health System that included Pulmonary Section Chief, Medical Director of E-ICU, Medical Director of Pulmonary Rehabilitation and Medical Director of the School of Respiratory Therapy. He relinquished these roles as he took on the responsibilities of the Chief Medical Officer for the American Lung Association. During his thirty-plus years in practice, he also served as the Principal Investigator for over 30 clinical trials in the fields of asthma, COPD, pulmonary fibrosis, pneumonia, and sleep apnea.
Dr. Rizzo had been a volunteer with the American Lung Association (ALA) since 1984 at both the local, regional, and national level. He served as Chairman of the National Board of Directors of the American Lung Association, 2011-2012. As a result of his service and achievements, he was awarded the Will Ross Medal for significant contribution to the prevention and control of lung disease in June 2015. He continued to serve as the senior Medical Advisor to the national office of the American Lung Association until being appointed the Chief Medical Officer for the organization in November 2018. In this role he collaborates with external partners to connect shared priorities and facilitate opportunities related to the American Lung Association’s mission of promoting lung health and preventing lung disease through research, advocacy and education, especially working on a level with the medical leadership of those external partners. In this role, Dr. Rizzo is currently the American Lung Association’s leading medical authority. He is their key medical advisor and leading media spokesperson.
In addition to smoking cessation, tobacco control and air quality, his topics include specific disease states such as COPD, Asthma, Sleep Apnea, and Lung Cancer, Climate Change Health Effects, E-cigarettes/vaping. The importance of recognizing and trying to eliminate some of the health care disparities that often involve these diseases is one of his concerns.
As a result of his involvement with the ALA, Dr. Rizzo has had the opportunity to educate both patients and the public as well as fellow professionals about the importance of preventive care and healthy lifestyles (particularly the role of cigarette smoking cessation) with regard to preserving lung function over the years. In his volunteer leadership roles he has testified before Congress on behalf of advancing lung disease research through funding of NIH and has lectured at American Lung Association meetings throughout the country. Within his role as the leading medical spokesperson for the Lung Association, Dr. Rizzo is a trusted resource for the public and news media, and is frequently featured in national leading news outlets, including CNN, The New York Times, ABC News, the TODAY Show, CBS Los Angeles, WPMT-TV and hundreds more.
To further deliver quality information and in-depth discussions about lung health, Dr. Rizzo also serves as the host of the Lung Association’s LungCastTM podcast, which has featured high-profile guests such as Dr. Anthony Fauci and is prdoduced by HCPLive and also hosts a monthly podcasr, Critical Observations in Pulmonary Medicine produced by Consultant360.
Mary Streck, MD
Dr. Mary Strek is a professor of Pulmonary Medicine and the Committee on Clinical Pharmacology and Pharmacogenomics at the University of Chicago. She investigates the phenotypic characteristics, outcomes and therapy for patients with chronic respiratory disease utilizing the Respiratory Clinical Research program, which she created to facilitate research in asthma, chronic obstructive pulmonary disease, bronchiectasis, and interstitial lung disease (ILD). She has been the principal investigator on numerous clinical research studies including pivotal trials of novel therapies. She is the director of an internationally recognized ILD program, with a registry and biospecimens core that includes > 1,800 patients and supervised creation of a bronchiectasis registry. She has trained and mentored junior faculty and fellows, many of whom are independent investigators and leaders in pulmonary medicine.
Novel contributions to the field of ILD and pulmonary fibrosis (PF) include: 1) recognition of occult autoimmunity as an etiologic factor and predictor of outcomes in ILD, 2) identifying that honeycombing is associated with worse outcomes in fibrotic ILD beyond idiopathic pulmonary fibrosis, 3) validation of a unique cluster analysis to characterize presenting features of patients with ILD which correlate with outcomes better than diagnostic guidelines, 4) Black race is associated with decreased mortality compared to White patients but ILD onset is younger, 5) mediastinal lymph node size and location predicts outcomes and is associated with altered cytokine production, and 6) inhalational exposures in the home and workplace are seen in a variety of forms of ILD beyond hypersensitivity pneumonitis including patients with connective tissue diseases.
Carla Vozone, PharmD, MBA
Carla Vozone is Vice President of Inhalation Strategy, Innovation and Partnerships at Catalent Pharma Solutions. Carla leads strategic growth initiatives for Catalent’s Inhalation business segment and oversees Product Development for Nasal and Pulmonary Delivery. She holds a PharmD and MSc in Pharmaceutical Technology from the Pharmacy School, University of Lisbon, a Master in Business Administration (MBA) with a specialization in Pharmaceutical Management from Rutgers Business School, New Jersey and a Certification in Business Development and Licensing from the University of Manchester. Carla is Immediate Past Chair of IPAC-RS, an industry consortium on regulatory science on orally inhaled and nasal drugs.
Helen Venn
Helen Venn is the Strategic Projects Director at Vitalograph and project lead for the development of cough monitoring solutions. She received her BSc in Medical Microbiology from the University of Leeds in 2001, following which she served for 8 years in the British Army finishing as a Captain in the Educational and Training Services branch where she completed a PGCE, PGDip and MSc in Educational Practice and Innovation. She is a fellow of the Society for Education and Training. Helen joined Vitalograph as a product manager in 2013, leading development of handheld spirometers and commercialization of the first version of the VitaloJAK. She has worked on product development projects and market strategy across the business since then and joined the board of directors in 2020.
Eric White, MD, ATSF
Eric White is a Senior Clinical Program Lead for IPF and other ILDs at Boehringer Ingelheim. In this role Eric is responsible for both early- and late-stage asset development globally for patients living with IPF and other forms of progressive fibrotic interstitial lung diseases. Eric earned his MD degree from the State University of New York Health Sciences Center at Brooklyn, and his Master of Science degree in Clinical Research Design and Statistical Analysis from the University of Michigan School of Public Health. Prior to joining the team at Boehringer-Ingelheim in 2020, Eric was Professor of Medicine in the Division of Pulmonary and Critical Care Medicine at the University of Michigan. In this role, Eric focused on pre-clinical (lab-based), translational, and clinical (patient-based) research into the pathogenesis and treatment of IPF and other progressive fibrotic interstitial lung diseases, with a focus on extracellular matrix biology and lung tissue remodeling and regeneration. Eric served as the Director of the Sarcoidosis Clinic as well as the Director of Translational Lung Fibrosis Research and as a specialist physician for patients with interstitial lung diseases.
